LYN and chronic myelogenous leukemia, BCR-ABL1 positive: Although there are currently no direct inhibitors of BIRC6, targeting Lyn or kinases that maintain BIRC6 expression or stability may have therapeutic potential in treating drug resistant CML or other cancers.